LOS ANGELES, January 22, 2024  (GLOBE NEWSWIRE) --  NeuroSigma, Inc. , a Los Angeles-based bioelectronics company commercializing the...

ATTENS (ADHD trial of external trigeminal nerve stimulation) Project , led by Professor Katya Rubia at the Institute of Psychiatry,...

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the...

LOS ANGELES, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, announced today that the...

Expansion of 2021 clinical supply agreement for Phase 2 clinical trial Next stage of trial to further assess efficacy of THIO in third...

CEO Andrew McKenzie Presenting on “Data-Driven Feeding: Artificial Intelligence and Machine Vision to Improve Cattle Intake” DALLAS, Aug....

THIO’s favorable disease control and overall response rates exceed reported standard-of-care data in third line treatment June 04, 2024...

Funds will help support the development of COYA 302 for the treatment of Frontotemporal Dementia (FTD) COYA 302’s combination therapeutic...